The healthcare sector is heterogeneous, with a wide dispersion in returns between the best- and worst-performing stocks. Active management can pay off. Occidental rises ahead of earnings, Delta sinks ...

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

After a generation of stagnation, interest in U.S. nuclear energy is sky high, thanks to artificial intelligence’s voracious ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna's mRNA-1273 vaccine helped prevent medically attended COVID-19 and related hospitalizations across multiple respiratory seasons among adults.

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...